Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Stimulant pharmacotherapy for adults with attention deficit hyperactivity disorder

cardiovascular effects and risk of sudden cardiac death

Pucci, Mark

doi: 10.1097/FAD.0000000000000019
Invited Review Article
Buy

Summary Drugs for attention deficit hyperactivity disorder are increasingly being used in adults. There have been concerns about the cardiovascular safety of stimulant attention deficit hyperactivity disorder drugs. Overall, studies in adults have shown small but statistically significant increases in heart rate and DBP and SBP, but have been relatively short term. Epidemiological studies have not clearly demonstrated an increased risk of sudden cardiac death, but a small increase in the risk cannot be ruled out.

Clinical Pharmacology and Therapeutics, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, UK

Correspondence to Mark Pucci, MB BCh, MRCP, Specialist Registrar, Clinical Pharmacology and Therapeutics, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2TH. E-mail: mark.pucci@uhb.nhs.uk

Editor: R E Ferner, MSc, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Assistant Editor: Mr C Anton, MA, MEng. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield, Denmark: Professor J S Schou; England: Dr J K Aronson; India: Professor N Gogtay; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand: Dr T Maling; Scotland: Dr D N Bateman; Wales: Professor P A Routledge.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.